Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Triple Negative Breast Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Solid Tumor 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1NSCLC 1Melanoma 1Gastrointestinal Stromal Tumors 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 51Gemcitabine 24Radiotherapy, Intensity-Modulated 21Docetaxel 20Fluorouracil 15camrelizumab 12Drug Therapy 11Radiotherapy 10toripalimab 8Chemoradiotherapy 8Capecitabine 8apatinib 7Induction Chemotherapy 7nimotuzumab 6endostar protein 6Endostatins 6sintilimab 5nedaplatin 5Bevacizumab 5fludarabine 4Cyclophosphamide 4spartalizumab 3fludarabine phosphate 3cisplatin-guanosine adduct 3SSRP1 protein, human 3Paclitaxel 3Injections 3Endoscopy 3tislelizumab 2Vitamin B 12 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Nasopharyngeal Carcinoma × famitinib × Clear all
NCT05020925 2021-08-25

SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Unknown
30 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡